Rgenix to Present Data on RGX-104 Clinical Activity at 2018 ASCO Annual Meeting

NEW YORK--(BUSINESS WIRE)-- Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today that it will present its abstract on RGX-104’s pharmacodynamic and clinical activity at the 2018 Annual Meeting of the American Society of Clinical Oncology. The meeting will take place in Chicago from June 1 through June 5.
The details of Rgenix’s presentation are as follows:
Event: 2018 ASCO Annual Meeting

Date: Monday, June 4, 2018

Time: 8:00 A.M. – 11:30 A.M. CDT

Description: Abstract #3095, “Pharmacodynamic and clinical activity of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies.”

Location: Hall A, McCormick Place, 2301 S. King Drive, Chicago, Il. 60616

About Rgenix

Rgenix, Inc., is a privately-held clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs that target key pathways in cancer progression. The company is pursuing several first-in-class drug candidates to treat cancers of high unmet need. Rgenix identifies novel cancer targets using a microRNA based target discovery platform originally developed by Rgenix’s scientific co-founders at The Rockefeller University and now exclusively licensed to Rgenix. The company brings together distinguished scientific founders, a seasoned Board, and a leadership team comprised of experienced drug developers. The company is funded by leading biotechnology investors, including Novo A/S, Sofinnova Partners, and Alexandria Venture Investments. For more information, please visit www.rgenix.com.

About RGX-104

RGX-104 is an orally-administered potent small molecule agonist of the Liver X Receptor (LXR) that is currently being evaluated in clinical studies. Activation of the LXR-ApoE pathway by RGX-104 stimulates the innate immune response in cancer via depletion of myeloid-derived suppressor cells and activation of dendritic cells, leading to stimulation of T cells and anti-tumor immunity. LXR activation also blocks the ability of tumors to recruit blood vessels. These combined effects result in suppression of tumor growth and metastasis in a broad array of animal tumor models. The LXR-ApoE pathway was originally identified as a cancer target using a novel microRNA-based discovery platform developed by Rgenix’s scientific co-founders at The Rockefeller University.

Rgenix is conducting a Phase 1a/b clinical trial of RGX-104 with or without nivolumab in patients with advanced solid malignancies—for more information about the clinical trial, please visit: https://clinicaltrials.gov/ct2/show/NCT02922764



Marion Janic, 212-223-4017


Source: Rgenix, Inc.

Back to news